Ask AI
SC ICI: Data

CE

SC ICI Delivery Strategies: Supporting Clinical Data for SC Immunotherapies 

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 13, 2026

Expiration: January 12, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Felip E, Burotto M, Zvirbule Z, et al. Results of a dose-finding phase 1b study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer. Clin Pharmacol Drug Dev. 2021;10:1142-1155.
  2. Burotto M, Zvirbule Z, Mochalova A, et al. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023;34:693-702.
  3. Burotto M, Zvirbule Z, Alvarez R, et al. Brief report: updated data from IMscin001 Part 2, a randomized phase III study of subcutaneous versus intravenous atezolizumab in patients with locally advanced/metastatic NSCLC. J Thorac Oncol. 2024;19:1460-1466.
  4. Burotto M, Zvirbule Z, Alvarez R, et al. IMscin001 Part 2 updated results: efficacy, safety, immunogenicity, healthcare provider perspectives, and patient-reported outcomes. Presented at: ESMO Congress 2025. Abstract 1854P.
  5. Capuzzo F, Zvirbule Z, Korbenfeld E, et al. Primary results from IMscin002: a study to evaluate patient- and healthcare professional-reported preferences for atezolizumab subcutaneous vs intravenous for the treatment of non-small cell lung cancer. JTO Clin Res Rep. 2025;6:100815.
  6. Majem M, Chewaskulyong B, Zvirbule Z, et al. Exploratory analyses of patient preferences for atezolizumab subcutaneous versus intravenous from the IMscin002 study in patients with non-small cell lung cancer. Oncol Ther. 2026;14:313.
  7. George S, Albiges L, Bourlon MT, et al. Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma: pharmacokinetics, efficacy, and safety results from CheckMate 67T. Presented at: ASCO Genitourinary Cancers Symposium 2024. Abstract LBA360.
  8. Albiges L, Bourlon MT, Chacón M, et al. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025;36:99-107.
  9. Adamczyk D, Bourlon MT, Albiges L, et al. Updated efficacy and safety results from CheckMate 67T: nivolumab subcutaneous vs intravenous in patients with previously treated advanced or metastatic clear cell renal cell carcinoma. Presented at: Oncology Nursing Society Congress 2025. Abstract 16944.
  10. Felip E, Rojas CI, Schenker M, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncol. 2025;36:775-785.
  11. Casarini IA, Kowalski DM, Caglevic C, et al. A phase II study of participant-reported preference for pembrolizumab administered subcutaneously or intravenously. Presented at: European Society for Medical Oncology Congress 2025. Abstract 3145P.
  12. ClinicalTrials.gov.